I haven't heard that directly from researchers at McGill in Quebec, but we do hear it from businesses. We hear from other international partners that they would like to see a stronger IP framework. Within the pharmaceutical industry, I'm sure you know, that's something they talk about.
It is something that needs to be worked on in Canada. We need to be more progressive in our IP and also in our policies and our approach to IP, and I think we're doing that.